11 completed, 3 active not recruiting, 2 terminated, 2 unknown. 13 Phase 2, 9 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 8, Active not recruiting 2, Unknown 2, Terminated 1 |
| Phase 1 | 9 | Completed 6, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow AZD4547: new trials by email Literature Review of AZD4547 trials Research Report on AZD4547
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC AZD4547, Tislelizumab - Urothelial Carcinoma | Phase 2 | Unknown | Abbisko Therapeutics Co, Ltd | 80 | 2022-09-30 | 2023-03-20 |
| A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 AZD4547 - Urothelial Carcinoma | Phase 1 / Phase 2 | Unknown | Abbisko Therapeutics Co, Ltd | 108 | 2021-06-03 | 2021-10-21 |
| ABSK091 Food Effect Study in Healthy Subjects ABSK091 tablet - Health, Subjective, Food-drug Interaction | Phase 1 | Completed | Abbisko Therapeutics Co, Ltd | 13 | 2020-09-08 | 2022-09-09 |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer AZD4547, MEDI4736, Olaparib - Muscle Invasive Bladder Cancer | Phase 1 | Active not recruiting | AstraZeneca | 117 | 2016-12-28 | 2026-10-01 |
| Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) FGFR Inhibitor AZD4547 - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Completed | National Cancer Institute (NCI) | 52 | 2016-05-31 | 2021-06-29 |
| Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion" AZD4547 - Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion, Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 14 | 2015-09-01 | 2019-05-29 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-26 |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer AZD4547, Vistusertib, Palbociclib - Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell | Phase 2 | Completed | University of Birmingham | 423 | 2015-05-13 | 2026-04-28 |
| Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Docetaxel, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis - FGFR1 Gene Amplification, FGFR1 Gene Mutation | Phase 2 / Phase 3 | Completed | SWOG Cancer Research Network | 43 | 2014-10-01 | 2021-05-27 |
| Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Docetaxel, Durvalumab, Erlotinib Hydrochloride - Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7 | Completed | SWOG Cancer Research Network | 1864 | 2014-07-08 | 2023-06-01 | |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients AZD2014, AZD4547, AZD5363 - Non-small Cell Lung Cancer Metastatic | Phase 2 | Completed | UNICANCER | 999 | 2014-04-23 | 2024-01-10 |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer AZD2014, AZD4547, AZD5363 - Metastatic Breast Cancer | Phase 2 | Active not recruiting | UNICANCER | 1460 | 2014-04-07 | 2025-01-15 |
| Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer docetaxel, AZD4547 - Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer | Phase 1 / Phase 2 | Completed | ECOG-ACRIN Cancer Research Group | 2 | 2014-01-15 | 2023-06-29 |
| AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL) AZD4547 / anastrozole or letrozole - Breast Cancer | Phase 1 / Phase 2 | Completed | Imperial College London | 52 | 2012-07-01 | 2022-08-22 |
| Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer AZD4547, paclitaxel - Gastro-oesophageal Junction Cancer, Gastric Cancer | Phase 2 | Terminated | AstraZeneca | 960 | 2011-11-01 | 2017-03-07 |
| Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients AZD4547, Exemestane, Placebo - FGFR Inhibition, Pharmacokinetics, Biomarkers, ER+ Breast Cancer | Phase 1 / Phase 2 | Completed | AstraZeneca | 127 | 2010-12-01 | 2016-02-11 |
| Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient AZD4547 - Cancer, Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 40 | 2010-11-01 | 2016-06-29 |
| Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours AZD4547 - Cancer, Advanced Solid Malignancies | Phase 1 | Terminated | AstraZeneca | 95 | 2009-10-21 | 2019-03-15 |
Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Transitional Cell (2) · Hematologic Neoplasms (2) · Lung Neoplasms (2) · Lymphoma (2) · Multiple Myeloma (2) · Neoplasms (2) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1)
AstraZeneca (5) · Abbisko Therapeutics Co, Ltd (3) · National Cancer Institute (NCI) (2) · SWOG Cancer Research Network (2) · UNICANCER (2) · Assistance Publique - Hôpitaux de Paris (1) · ECOG-ACRIN Cancer Research Group (1) · Imperial College London (1) · University of Birmingham (1)
France (7) · United States (7) · United Kingdom (6) · Canada (4) · Germany (3) · Italy (3) · Spain (3) · Belgium (2) · China (2) · Czechia (2) · Hungary (2) · Japan (2) · Romania (2) · Taiwan (2) · Bulgaria (1)
Vassiliki Papadimitrakopoulou (2) · Amitabha Chakrabarti (1) · Anne Armstrong (1) · Charles Rudin (1) · Dingwei Ye, Professor (1) · Donal Landers (1) · Donal Landers, Dr (1) · Eric Van Cutsem, MD PHD (1) · Gary W Middleton (1) · Hendrik-Tobias Arkenau, MD, PhD (1) · Hideo Saka, MD, PhD (1) · Iain MacPherson (1)
PMID 26410619, PMID 32463741, PMID 26586415, PMID 28070720, PMID 32067679, PMID 32203306, PMID 32669708, PMID 33048619, PMID 33125909, PMID 35133871, PMID 35138919, PMID 35688802, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39111731, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40069402, PMID 40865033, PMID 41066729
2014 (2), U10CA180820 (2), U10CA180888 (2), U24CA196172 (2), 2015 (1), U10CA021115 (1)